location: Home > english > NEWSROOM > March 2017 (1) >
Luqa Acquires Arista, strengthening its position in China medical aesthetics market
source:admin time:2017-08-31

Luqa Acquires Arista, strengthening its position in China medical aesthetics market

March 3rd, 2017 Hong Kong, China
Luqa Pharmaceuticals (“Luqa”) today announced that it has entered into a definitive agreement under which Luqa will acquire all of the outstanding common stock of Arista, a company focused on aesthetic and surgical solutions. This transaction advances Luqa’s strategy of becoming a China leader in the fast growing, multi-billion dollar aesthetic market and a provider of innovative medical solutions.

The new Luqa will be distinguished in the marketplace by its ability to offer a broad suite of solutions to enable healthcare professionals to achieve excellent patient results and satisfaction. The acquisition will bring the flagship product Aethoxysklerol® for the treatment of varicose veins. Luqa will offer healthcare providers a broader range of high quality treatment options, further enhancing Luqa’s customer relationships, its competitive position and enable Luqa to capitalize on opportunities to effectively launch new products from its product pipeline.

“Today’s announcement is a significant next step in our journey to become the leader in China’s aesthetics market. These additions to Luqa’s strong platform strengthen our operating foundation and build on Luqa’s mission of providing innovative and effective products with customer centric solutions for the medical community and the patients we serve,” Robert Braithwaite, CEO of Luqa, said. “We are extremely pleased with this transaction, which has been strongly supported by Luqa shareholders. It ensures even greater potential for future growth in the fast growing aesthetics and medical business we focus on. With this acquisition we expand our product offering, increase our direct commercial presence in China and expand our reach to the whole of the Greater China region.”

Zona Yim, Managing Director of Arista, “We are pleased to join Luqa. I believe this combination offers a platform for future growth as well as expanded opportunities for our company as a whole. I am confident that with Luqa’s energy, resources, product portfolio and robust pipeline, we will be better positioned to develop and market the solutions our customers need. ”

About Arista
Arista is a company specializing in the commercialization of quality pharmaceutical products and medical devices targeting the medical aesthetic market. Arista provides access for foreign manufacturers entering into China through in-licensing partnerships and provides a comprehensive range of services such as market feasibility studies, regulatory works and brand management synergized to create fast market penetration and high brand value.

About Luqa
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialise innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty segments in China.

For more information about Luqa Pharmaceuticals
Mr. Luis Juste
Business Development Director
ljuste@luqapharma.com
www.luqapharma.com